FDA 授予 Candel Therapeutics 治疗高级别神经胶质瘤候选药物 CAN-3110 快速通道资格后，Candel Therapeutics 股价上涨 25%。 Candel Therapeutics' shares rose 25% after the FDA granted fast-track designation for its CAN-3110 drug candidate treating high-grade glioma.
Candel Therapeutics 的 CAN-3110 候选药物获得 FDA 快速通道指定后，该公司股价周二飙升近 25%。 Candel Therapeutics' shares surged by nearly 25% on Tuesday after the company received FDA Fast-Track Designation for its CAN-3110 drug candidate. 该指定涵盖 CAN-3110 在治疗复发性高级别神经胶质瘤患者中的用途，以提高总体生存率。 This designation covers the use of CAN-3110 in treating patients with recurrent high-grade glioma for improved overall survival. Cann-3110 是一种针对侵袭性脑肿瘤的一流溶瘤免疫疗法。 Cann-3110 is a first-in-class oncolytic immunotherapy that targets aggressive brain tumors.